The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …

Intratumoral immune cells are crucial for tumor control and antitumor responses during
immunotherapy. Immune cell trafficking into tumors is mediated by binding of specific …

Background Activating mutations of EZH2, an epigenetic regulator, are present in
approximately 20% of patients with follicular lymphoma. We investigated the activity and …

Immune checkpoint blockade therapy with anti-PD-1 monoclonal antibody (mAb) is a
treatment for colorectal cancer (CRC). However, some patients remain unresponsive to PD …

The ever-increasing understanding of the complexity of factors and regulatory layers that
contribute to immune evasion facilitates the development of immunotherapies. However, the …

An inflammatory microenvironment, either conferred by an underlying chronic overt or
smoldering inflammatory condition constitutes a prerequisite and fuel to essentially all …

Prostate cancers are considered to be immunologically 'cold'tumors given the very few
patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of …

Chromatin is a macromolecular complex predominantly comprising DNA, histone proteins
and RNA. The methylation of chromatin components is highly conserved as it helps …

The past decade has seen the emergence of immunotherapy as a prime approach to cancer
treatment, revolutionizing the management of many types of cancer. Despite the promise of …